Your browser doesn't support javascript.
loading
Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy.
Kim, Chang Gon; Hwang, Sang Hyun; Kim, Kyung Hwan; Yoon, Hong In; Shim, Hyo Sup; Lee, Ji Hyun; Han, Yejeong; Ahn, Beung-Chul; Hong, Min Hee; Kim, Hye Ryun; Cho, Byoung Chul; Cho, Arthur; Lim, Sun Min.
Affiliation
  • Kim CG; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Hwang SH; Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Kim KH; Department of Radiation Oncology, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Yoon HI; Department of Radiation Oncology, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Shim HS; Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Lee JH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Han Y; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Ahn BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Hong MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Cho BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Cho A; Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.
  • Lim SM; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Centre, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.
Ther Adv Med Oncol ; 14: 17588359211068732, 2022.
Article de En | MEDLINE | ID: mdl-35035536
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies / Risk_factors_studies Langue: En Journal: Ther Adv Med Oncol Année: 2022 Type de document: Article Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies / Risk_factors_studies Langue: En Journal: Ther Adv Med Oncol Année: 2022 Type de document: Article Pays de publication: Royaume-Uni